Video

Dr. Rao on the Histogenesis of Endometrial Cancer

Author(s):

Jianyu Rao, MD, professor and chief of Cytopathology, University of California, Los Angeles, discusses the histogenesis of endometrial cancer.

Jianyu Rao, MD, professor and chief of Cytopathology, University of California, Los Angeles, discusses the histogenesis of endometrial cancer.

There is some overlap in the histogenesis of endometrial cancer and ovarian cancer, says Rao. Cervical cancer, however, has a completely different histogenesis that is often related to an HPV infection, says Rao. Endometrial cancer is typically classified by 2 categories—tumors that are associated with high levels of estrogen, and tumors that are associated with low levels of estrogen.

Endometrial cancers can be classified as type 1 endometrial tumors or type 2 serous cancers. That distinction is often made by histology. Testing for mismatch repair deficiency and microsatellite instability is now recommended to help improve classification and treatment. Pembrolizumab (Keytruda) is the first agent to be FDA-approved based only on histology.

Ovarian cancer is identified by estrogen, but the other gynecologic cancers are more related to the genetic changes of the particular gene in question, states Rao.

Related Videos
Alan Tan, MD, genitourinary oncology and melanoma specialist, Vanderbilt-Ingram Cancer Center; associate professor, medicine, Division of Hematology Oncology, Vanderbilt University Medical Center
Zosia Piotrowska, MD, MHS, instructor, Harvard Medical School; medical oncologist, Massachusetts General Hospital
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD